FMC shares closed up 1.2% following first quarter results that modestly surpassed internal guidance midpoints. Performance was mixed, as FX and volume supported modest outperformance, but sales and margins reflected ongoing market competition and pressure from generics.

• First quarter sales totaled $762 million, $12 million above FMC’s guidance midpoint; sales declined 4% year-over-year, but rose 1% excluding India.
• EBITDA reached $72 million, exceeding the high end of guidance by $17 million, with FX, volume, and cost controls all contributing favorably.
• Sales of new active ingredients doubled year-over-year, while core portfolio performance lagged due to competitive pricing and post-patent headwinds, especially in LatAm and Asia.
• Price declined 6% overall, nearly half attributed to lower pricing to diamide partners and the rest driven by branded Rynaxypyr repositioning and pressure on legacy products.
• Strategic initiatives advanced, including progress on $1 billion in targeted debt reduction and the late-stage sale process of the India commercial business; Board continues to evaluate broader alternatives.